pharma news today obesity drugs glp-1 october 2025 Agonists Weight Loss Market Report, 2025-2030 Obesity GLP-1 Market

Looking Ahead As the market evolves, stakeholders are watching for regulatory updates and court decisions that could reshape the boundaries of compounding

Shima Hadidchi MD Offered Semaglutide GLP-1 Injections to Help Obese Adults to Achieve Substantial Weight Loss & Improved Overall Health.

As a result, they are effective treatment options for people with T2D, achieving glycated haemoglobin reductions, weight loss and potential cardiovascular benefit, as monotherapy or as add-on to other glucose-lowering therapies

By Sabina Paglialunga, PhD & Aernout van Haarst, PhD Senior Directors Scientific Affairs Glucagon-Like Peptide-1 (GLP-1) receptor agonists first came to the market in 2005 as a type 2 diabetes mellitus treatment, and they have been making headlines again for their weight reduction effects

This landmark policy change recognises obesity as a chronic disease and recommends that GLP-1 antagonists are used by adults for the long-term treatment of obesity

Suitable for a range of dietary lifestyles